Applying the CYP2D6 metabolizer subgroup as a binary instrument for metoprolol exposure, we were not able to detect an association between genotype and CV death or a composite of MACE among post-MI patients during 3 years follow-up, indicating no beneficial effect of high vs. low dosage of metoprolol. This evidence concerns the gene CYP2D6 and myocardial infarction.